Liesl Page‐Shipp - Concepedia

Author

Liesl Page‐Shipp

Also Known As

Barnard, Antonia, Clouse, Kate, L Page-Shipp, L. Page-Shipp, L. S Page-Shipp, Liesl Page-Shipp, Liesl Page‐Shipp, Liesl Shirley Page-Shipp, Page-Shipp, Liesl, Sanne, I.

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

University of the Witwatersrand Aurum Institute Right to Care University of Cape Town National Health Laboratory Service

About

Liesl Page‐Shipp is an author at University of the Witwatersrand specializing in medicine, tuberculosis, and preventive treatment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	815
2	Epidemiology	3	3	157
3	Health Sciences	1	1	72
4	Public Health	1	1	18
5	Health Policy	1	1	18

Liesl Page‐Shipp

Publications

Citations

H-Index

Page 1

	Year	Citations
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis Andreas H. Diacon, Alexander S. Pym, Martin P. Grobusch, New England Journal of Medicine	2009	836
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt, The Lancet Pulmonary TuberculosisPhase 2BTuberculosis PreventionPharmacologyTuberculosis	2015	248
Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study Keertan Dheda, Karen Shean, Alimuddin Zumla, The Lancet Pulmonary TuberculosisTreatment And PreventionTuberculosis PreventionClinical EpidemiologySouth Africa	2010	248
Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis M. Plit, Ronald Anderson, C.E.J. Van Rensburg, European Respiratory Journal Pulmonary TuberculosisAntibioticsSpirometric ParametersSevere Pulmonary TuberculosisImmunology	1998	138
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention Lindsey R. Baden, Etienne Karita, Gaudensia Mutua, Annals of Internal Medicine	2016	84
Human Immunodeficiency Virus–1 RNA Levels and CD4 Lymphocyte Counts, during Treatment for Active Tuberculosis, in South African Patients Lynn Morris, Desmond J. Martin, Helba Bredell, The Journal of Infectious Diseases	2003	75
False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications [Technical note] Annelies Van Rie, K. Mellet, M-A. John, The International Journal of Tuberculosis and Lung Disease World Health OrganizationAntibiotic ResistanceDrug ResistanceXpert® Mtb/rifResistance Mutation (Virology)	2012	72
Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level Kate Clouse, Liesl Page‐Shipp, Heather Dansey, South African Medical Journal Point-of-care TestingRoutine Point-of-care DiagnosisTuberculosis PreventionDiagnosisPrimary Care Level	2012	67
Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa Annelies Van Rie, Liesl Page‐Shipp, Colleen F. Hanrahan, The International Journal of Tuberculosis and Lung Disease	2013	38
Effects of Anticoagulants and Temperature on Expression of Activation Markers CD11b and HLA-DR on Human Leukocytes Sharon Shalekoff, Liesl Page‐Shipp, Caroline T. Tiemessen Clinical and Diagnostic Laboratory Immunology	1998	31

Page 1